Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Exanta "not approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca's anticoagulant Exanta (ximelagatran) is "not approvable," the company announces Oct. 8. The agency's decision, reached two weeks ahead of the Oct. 23 user fee date, is in line with the Cardiovascular & Renal Drugs Advisory Committee's Sept. 10 recommendation against approval for all three indications being sought. Liver safety has been a key safety concern with Exanta; AstraZeneca previously indicated that labeling would likely include requirements for regular liver function monitoring (1Pharmaceutical Approvals Monthly Jan. 1, 2004, p. 17). During an Oct. 6 conference call, VP Hamish Cameron described the situation as "a clash between what might be termed regulatory medicine and clinical medicine"...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel